- Home
- JANX vs BHE Comparison
JANX vs BHE Comparison
Compare JANX & BHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- BHE
- Stock Information
- Founded
- JANX 2017
- BHE 1979
- Country
- JANX United States
- BHE United States
- Employees
- JANX N/A
- BHE N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- BHE Electrical Products
- Sector
- JANX Health Care
- BHE Technology
- Exchange
- JANX Nasdaq
- BHE Nasdaq
- Market Cap
- JANX 1.4B
- BHE 1.4B
- IPO Year
- JANX 2021
- BHE 1990
- Fundamental
- Price
- JANX $23.15
- BHE $37.92
- Analyst Decision
- JANX Strong Buy
- BHE Strong Buy
- Analyst Count
- JANX 11
- BHE 2
- Target Price
- JANX $76.55
- BHE $46.50
- AVG Volume (30 Days)
- JANX 714.6K
- BHE 298.1K
- Earning Date
- JANX 11-05-2025
- BHE 10-29-2025
- Dividend Yield
- JANX N/A
- BHE 1.76%
- EPS Growth
- JANX N/A
- BHE N/A
- EPS
- JANX N/A
- BHE 1.05
- Revenue
- JANX $439,000.00
- BHE $2,588,733,000.00
- Revenue This Year
- JANX N/A
- BHE $0.03
- Revenue Next Year
- JANX $130.50
- BHE $5.83
- P/E Ratio
- JANX N/A
- BHE $36.93
- Revenue Growth
- JANX N/A
- BHE N/A
- 52 Week Low
- JANX $21.73
- BHE $30.73
- 52 Week High
- JANX $71.71
- BHE $52.57
- Technical
- Relative Strength Index (RSI)
- JANX 48.91
- BHE 38.86
- Support Level
- JANX $21.73
- BHE $38.97
- Resistance Level
- JANX $24.54
- BHE $41.31
- Average True Range (ATR)
- JANX 1.07
- BHE 0.96
- MACD
- JANX -0.06
- BHE -0.24
- Stochastic Oscillator
- JANX 47.38
- BHE 0.13
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About BHE Benchmark Electronics Inc.
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia and Europe of which key revenue is derived from the Americas.